Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Exculture B V maintains 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The prosecution is centralized, featuring a single distinct examiner and a sole distinct art unit. SABILA, MERCY HELLEN is the busiest examiner for this portfolio, currently overseeing 1 pending office action.
The presence of prosecution activity in the Biotechnology & Pharmaceuticals sector indicates a focused or early-stage effort. Because the portfolio utilizes only a single distinct examiner, the interaction is limited to the perspective of SABILA, MERCY HELLEN. The use of a sole distinct art unit further reinforces this centralized approach, as all current pending matters are subject to the same departmental oversight. For a practitioner, this means that the prosecution strategy cannot be diversified across different examiners to mitigate risk. Every pending matter for this entity is currently subject to the same examination criteria and individual examiner discretion.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SABILA, MERCY HELLEN | 1 | 57.0% | +46.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17288463 | PRODUCTION OF BIOMEDICAL COMPOUNDS BY ENRICHMENT CULTURES OF MICROORGANISMS | SABILA, MERCY HELLEN | 49d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17288463 | PRODUCTION OF BIOMEDICAL COMPOUNDS BY ENRICHMENT CULTURES OF MICROORGANISMS | SABILA, MERCY HELLEN | 49d overdue |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17288463 | PRODUCTION OF BIOMEDICAL COMPOUNDS BY ENRICHMENT CULTURES OF MICROORGANISMS | SABILA, MERCY HELLEN | 1654 | §103§112 | Non-Final OA | 49d overdue | Pending | Apr 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial